Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

News Daily News

Take Heed of Sex Differences in Peripheral Vascular Disease: AHA

Michael O'Riordan

March 13, 2025

News Daily News

As More Peripheral Interventions Go Radial, the AHA Offers Some Insights

L.A. McKeown

December 12, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

News Daily News

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

L.A. McKeown

August 05, 2022

News Daily News

PAD Continues to Elude Clinicians, Despite Gains: AHA

L.A. McKeown

August 05, 2021

The finding, from a study with a mean follow-up of 2-and-a-half years, bolsters support for trials and device use to continue.

News Daily News

SWEDEPAD: No Mortality Signal With Paclitaxel in PAD

L.A. McKeown

December 18, 2020

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Conference News LINC 2020

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

L.A. McKeown

January 31, 2020

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

Caitlin E. Cox

January 24, 2020

News Daily News

Endo-First Strategy Matches Surgery in Select CLI Patients: Retrospective Data

Caitlin E. Cox

July 30, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Conference News CRT 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Yael L. Maxwell

March 14, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

News Conference News ISET 2019

PVI in Symptomatic Lower-Extremity PAD Offers Multiple Benefits, Even 2.5 Years Later

Caitlin E. Cox

February 07, 2019

News Conference News ISET 2019

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

Caitlin E. Cox

January 29, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

L.A. McKeown

December 18, 2018

Advertisement

Take Heed of Sex Differences in Peripheral Vascular Disease: AHA

As More Peripheral Interventions Go Radial, the AHA Offers Some Insights

Top Endovascular News of 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

PAD Continues to Elude Clinicians, Despite Gains: AHA

SWEDEPAD: No Mortality Signal With Paclitaxel in PAD

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

FDA’s First Take on New Paclitaxel Concerns in CLI

Endo-First Strategy Matches Surgery in Select CLI Patients: Retrospective Data

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

PVI in Symptomatic Lower-Extremity PAD Offers Multiple Benefits, Even 2.5 Years Later

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content